[26], loss of normal p53 function results in resistance to ALK‐TKIs in ALK+ NSCLC and combined proteasome inhibitor with alectinib is a promising therapy for ALK+TP53 NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.